Device Trial Radar · NCT03226626
Tumescent Anesthesia Antibiotic Delivery (TAAD)
Last checked: Nov 20, 2026Latest source record: Feb 2, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
330
Planned (sponsor's estimate)
Start
Dec 1, 2021
Primary completion
Jan 1, 2022
Study completion Jul 31, 2022
Sponsor
- Lead sponsor
- HK Surgical, Inc.Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- University of California, Riverside
- First posted
- Jul 24, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter randomized clinical trial (RCT) comparing two modes of antibiotic delivery: Control: Intravenous Antibiotic Delivery (IVAD) Treatment: IVAD + TAAD The Food \& Drug Administration (FDA) has approved our Investigational New Drug (IND) application to conduct this RCT. An IND application was necessary because subcutaneous injection of antibiotics in general, and cefazolin and metronidazole in particular are considered to be "off-label". In addition, the tumescent formulation of cefazolin (1gm) and metronidazole (500mg/100ml) in a dilute solution of lidocaine (1gm), epinephrine (1mg) in 100ml and sodium bicarbonate (10mEq/10ml) added a 1000ml bag of 0.9% sodium chloride (total volume 1210ml) is also considered "off-label." This trial will also prospectively study the HK Surgical SubQKath, an over-the-needle subcutaneous catheter specifically designed to deliver relatively large volumes of a relatively dilute TAAD solution. The TAAD trial will document the safety and efficacy of the HK SubQKath
Conditions
- Surgical Site Infection
- Thrombosis
- Sepsis
Interventions
Tumescent Anesthesia and antibiotic delivery (TAAD) plus IVADDrug
Concomitant tumescent anesthesia antibiotic delivery (TAAD) \& Intravenous antibiotic delivery (IVAD).
SubQKathDevice
The device intervention consists of using the SubQKath device to provide subcutaneous delivery of antibiotics.
Primary outcomes
What the sponsor says the trial is designed to measure.
- surgical site infection (SSI)Time frame: within 30 of surgical procedure
3 more outcomes with a free account
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.